|
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223). |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Pfizer |
Consulting or Advisory Role - Astellas Medivation; Janssen |
Speakers' Bureau - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Oncology; Bayer; Janssen; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi; Sofie |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Blue Earth Diagnostics; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |